Cullinan Therapeutics, Inc. (CGEM) NASDAQ

8.48

-0.08(-0.93%)

Updated at October 21 04:00PM

Currency In USD

Cullinan Therapeutics, Inc.

Address

One Main Street

Cambridge, MA 02142

United States of America

Phone

617 410 4650

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Employees

111

First IPO Date

January 08, 2021

Key Executives

NameTitlePayYear Born
Mr. Nadim AhmedPresident, Chief Executive Officer & Director1.17M1968
Ms. Mary Kay Fenton CPAChief Financial Officer544,1531964
Dr. Patrick A. Baeuerle Ph.D.Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board763,7341958
Dr. Jeffrey Jones M.B.A., M.D., M.P.H.Chief Medical Officer844,8261971
Mr. Kevin A. JohnstonChief Technical Operations Officer0N/A
Mr. Steve AndreChief Human Resources Officer0N/A
Ms. Rose WeldonSenior Vice President of Corporate Affairs0N/A
Ms. Jacquelyn L. Sumer J.D.Chief Legal Officer, Chief Compliance Officer & Corporate Secretary01978
Dr. Corinne Savill Ph.D.Chief Business Officer01959
Dr. Jennifer Michaelson Ph.D.Chief Scientific Officer01967

Description

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.